Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520275 | 1.00 | KDM4E (0.56) | KDM4EKCNMA1MAOBCYP11B2ALOX12 | |
| SCHEMBL25442716 | 0.89 | MEN1 (0.57) | KDM4EKCNMA1RAB9AMEN1KMT2A | |
| SCHEMBL30520433 | 0.85 | MEN1 (0.53) | KDM4EALOX12RAB9AMEN1KMT2A | |
| SCHEMBL19197930 | 0.85 | MEN1 (0.53) | KDM4EALOX12RAB9AMEN1KMT2A | |
| SCHEMBL19197790 | 0.83 | CYP11B2 (0.53) | KDM4ECYP11B2RAB9AMEN1KMT2A | |
| SCHEMBL30520200 | 0.83 | CYP11B2 (0.53) | KDM4ECYP11B2RAB9AMEN1KMT2A | |
| SCHEMBL3254598 | 0.80 | KDM4E (0.59) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL30520309 | 0.80 | KDM4E (0.59) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL30520641 | 0.80 | PDE4B (0.58) | KDM4EALOX12RAB9AKMT2AALPL | |
| SCHEMBL19198640 | 0.80 | PDE4B (0.58) | KDM4EALOX12RAB9AKMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-9725441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | KDM4E 26/4885KCNMA1 1965/4885MAOB 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.